TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31322086
Drug: Standard antianginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antianginal and antiarrhythmic therapy only
Study: 23122974
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg loading dose followed by 30 μg/kg/min infusion)
Study: 30260460
Drug: L-arginine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 6 g/day
Study: 27392904
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin for 6 weeks
Study: 25917265
Drug: Balneotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy with mud-pack and hot pool treatments
Study: 21115455
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Study: 21115454
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g plus aztreonam 1 g every 12 h for 5-14 days
Study: 16758259
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily for 18 days
Study: 16758259
Drug: Baseline S‐warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline S‐warfarin AUC(0‐infinity)
Study: 16758259
Drug: Inhibition period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition period S‐warfarin AUC(0‐infinity)
Study: 8966087
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 ml daily for 12 weeks)
Study: 7880657
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (SDSA) with a 24‐gauge x 103‐mm Sprotte spinal needle
Study: 7880657
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (SDSA)
Study: 7880657
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia (CSA) and Single-dose spinal anaesthesia (SDSA)
Study: 2906764
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (OC)
Study: 2148146
Drug: Progestogen-only pill
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only pill
Study: 28703949
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment assignment
Study: 26714490
Drug: Bowel-cleansing preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel-cleansing preparations satisfaction measure (Domain 1)
Study: 22053621
Drug: Hemodialyzed patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialyzed patients without glucose (HD-g(-))
Study: 22053621
Drug: Hemodialyzed patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialyzed patients with glucose (HD-g(+))
Study: 17111989
Drug: Standard psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychiatric treatments (treatment as usual)
Study: 12583870
Drug: Granisetron (GRA)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (GRA) 1 mg/ml injected into the masseter muscle
Study: 10898121
Drug: Amtolmetin guacyl
Normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin guacyl (600 mg on an empty stomach, once daily for 30 days)
Study: 10898121
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg on a full stomach, once daily for 30 days)
Study: 1622733
Drug: PSK (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK (3.0 g orally before surgery, daily or every other day)
Study: 26872703
Drug: Web-based coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based coaching program (fully automated) including education, motivation, exercise guidance, daily text message reminders, and weekly feedback.
Study: 24155058
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg once daily for 14 days plus etravirine 800 mg twice daily for 21 days (days 8-21)
Study: 24155058
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily for 13 days plus etravirine 200 mg twice daily for 8 days (days 6-13)
Study: 22015542
Drug: SMART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART treatment (budesonide/formoterol 80/4.5 μg Turbuhaler®, two puffs once daily and extra inhalations as needed)
Study: 22015542
Drug: SMART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART treatment
Study: 22015542
Drug: UC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC treatment
Study: 20439575
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (2 mg/d subcutaneously)
Study: 20439575
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (2 mg/d)
Study: 20439575
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (2 mg/d) with testosterone (250 mg/wk intramuscularly)
Study: 625655
Drug: Diclofenac (Voltaren)
Normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac (Voltaren) 75 mg daily from week 4
Study: 625655
Drug: Naproxen (Proxen)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (Proxen) 500 mg daily from week 4
Study: 24055681
Drug: VEN‐Progressive Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN‐Progressive Muscle Relaxation therapy (PMR)
Study: 20739054
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg once daily)
Study: 19169289
Drug: Pegfilgrastim 12
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 12 mg
Study: 19169289
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim (10 microg/kg for < or =7 days)
Study: 19169289
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim (5 microg/kg/day for < or =14 days)
Study: 15480402
Drug: Pamidronate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate infusion
Study: 11296091
Drug: SR141716 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR141716 (90 mg)
Study: 11296091
Drug: SR141716 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR141716 (1, 3, 10, 30, and 90 mg)
Study: 9416985
Drug: Other active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other active drugs
Study: 8293730
Drug: Anxiety before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety before the 1st infusion
Study: 3323290
Drug: iv calcium
Normalized name: Viactiv Calcium Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv calcium infusion
Study: 3323290
Drug: oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral diltiazem administration for one week
Study: 3323290
Drug: acute iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute iv diltiazem infusion
Study: 3323290
Drug: calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium and diltiazem treatments
Study: 24144628
Drug: Potato-derived balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato-derived balanced 6% HES 130/0.42 with 500 mL of Ringer's lactate (HESPRL)
Study: 24144628
Drug: Waxy maize-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waxy maize-derived balanced 6% HES 130/0.4 with 500 mL of Ringer's lactate (HESMRL)
Study: 14743119
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 12-15 ml of ropivacaine 0.75% and fentanyl 5 microg/ml followed by light general anesthesia and postoperative epidural analgesia with ropivacaine 0.2% and fentanyl 2 mg/ml
Study: 14743119
Drug: Inhalatory or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalatory or intravenous general anesthesia and intravenous tramadol postoperative analgesia
Study: 11078493
Drug: 4‐HPR (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐HPR (200 mg/d)
Study: 27049107
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg sodium hyaluronate plus saline solution
Study: 22664486
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy with an implantable defibrillator (CRT-D)
Study: 18759963
Drug: Combined anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anticoagulation with unfractioned heparin (UFH) and tirofiban
Study: 12149235
Drug: G‐CSF‐mobilized peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF‐mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Study: 9952152
Drug: Midazolam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (100 microg/kg) administered as a rapid intravenous bolus dose every 4-6 hours
Study: 7593731
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 to 450 mg daily
Study: 29297950
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vaginal progesterone
Study: 28707771
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone
Study: 30452422
Drug: Edasalonexent (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (33 mg/kg/day)
Study: 30452422
Drug: Edasalonexent (67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (67 mg/kg/day)
Study: 30452422
Drug: Edasalonexent (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (all doses)
Study: 30452422
Drug: Edasalonexent (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (after 7 days of dosing)
Study: 18043999
Drug: Cilnidipine 10
Normalized name: Cilnidipine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine 10 mg
Study: 21539882
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of PCV
Study: 21539882
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of PCV
Study: 21539882
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of PCV
Study: 21539882
Drug: 0 doses
Normalized name: mometasone furoate 220 mcg/actuation (30 doses) INHALATION AEROSOL POWDER, BREATH ACTIVATED (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 doses of PCV
Study: 19388864
Drug: D&G combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&G combination (3 g)
Study: 19388864
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 capsules)
Study: 19388864
Drug: Open-label D&G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label D&G (1.5 g/day for 6 months)
Study: 2898268
Drug: BRL 26830A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 26830A, 200 mg daily for two weeks then 400 mg daily for 18 weeks
Study: 30347431
Drug: Verubecestat (MK-8931)
Normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (MK-8931) 20 mg
Study: 30347431
Drug: Verubecestat (MK-8931)
Normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (MK-8931) 100 mg
Study: 30347431
Drug: Verubecestat (MK-8931)
Normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (MK-8931) 450 mg
Study: 30347431
Drug: Verubecestat (MK-8931)
Normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (MK-8931) 80 mg once daily for 14 days
Study: 30347431
Drug: Verubecestat (MK-8931)
Normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (MK-8931) 150 mg once daily for 14 days
Study: 28399935
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with VR training
Study: 25794299
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylphenidate (up to 5mg×3) for 4 weeks
Study: 25794299
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose methylphenidate (up to 20mg×3) for 4 weeks
Study: 25794299
Drug: Methylphenidate (60mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (60mg/day spread over three doses)
Study: 25794299
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medication for 4 weeks)
Study: 23211647
Drug: FVFP supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVFP supplement (fruit plus vegetable concentrate, fish oil and probiotics)
Study: 23211647
Drug: FVFP supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVFP supplement
Study: 21477682
Drug: Mifepristone+misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone+misoprostol (200 mg mifepristone and 800 mcg buccal misoprostol 24 h later)
Study: 21477682
Drug: Misoprostol-only (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol-only (800 mcg buccal misoprostol 24 h apart)
Study: 16421418
Drug: Standard-Dose Anthracycline-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Anthracycline-Based Chemotherapy (SD-CT)
Study: 3072307
Drug: Multivitamin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin preparation for 12 days
Study: 28626756
Drug: MyrLiq 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyrLiq 400 mg/day
Study: 28626756
Drug: MyrLiq 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyrLiq 200 mg/day
Study: 24330826
Drug: Agomelatine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25 mg/day p.o.) with immediate substitution
Study: 24330826
Drug: Agomelatine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25 mg/day p.o.) with short-tapering of previous drug
Study: 24330826
Drug: Agomelatine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25 mg/day p.o.) with long-tapering of previous drug
Study: 18441708
Drug: monopril +
Normalized name: fosinopril sodium Oral Tablet [Monopril]
Approvals — FDA: no, EMA: no, PMDA: no
Description: monopril + propranolol + heparin
Study: 18441708
Drug: propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol + heparin
Study: 12612990
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutritional supplement 2 hours before lunch
Study: 12612990
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutritional supplement 30 minutes before lunch
Study: 7899060
Drug: Enhanced MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced MRI (superparamagnetic iron oxide); pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI); contrast medium dose: 10 mumoles Fe/kg, administered intravenously for more than 30 minutes.
Study: 2559272
Drug: DTC 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTC 200 mg/m2 intravenously weekly for 16 weeks
Study: 30783794
Drug: Chlorpromazine 25
Normalized name: chlorpromazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 25 mg
Study: 28251894
Drug: Dermocosmetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermocosmetic treatment (containing lipohydroxyacid, nicotinamide, and piroctone-olamine)
Study: 21099447
Drug: Maternal ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal ω‐3 fatty acid supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Study: 19221150
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with prophylactic cranial irradiation
Study: 19221150
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy without prophylactic cranial irradiation
Study: 9174558
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 IU bd)
Study: 9174558
Drug: Heparin (12,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (12,500 IU bd)
Study: 8198237
Drug: Open challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open challenge with food additives (coloring agents, preservatives, citric acid, flavoring agents) using carbonated lemonade; two doses: low dose and 10-fold higher dose.
Study: 8198237
Drug: Double-blind challenge
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind challenge with food additives (preservatives, coloring agents, citric acid) using gelatin capsules.
Study: 29609646
Drug: Stereotactic body-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body-radiotherapy (SBRT) boost dose of 18 Gy
Study: 29609646
Drug: Stereotactic body-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body-radiotherapy (SBRT) boost dose of 21 Gy
Study: 29609646
Drug: Stereotactic body-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body-radiotherapy (SBRT) boost (both doses)
Study: 9120932
Drug: Oral antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiandrogen (nilutamide)
Study: 27586458
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Agents (WAJA)
Study: 22055330
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) for 8 weeks
Study: 22055330
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus SSRIs
Study: 18380940
Drug: Vaccination (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination (twice before surgery or conservative treatment)
Study: 16034289
Drug: Shelter-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shelter-based intervention including intensive outreach by a psychiatric social worker and availability of weekly psychiatrist visits
Study: 12464463
Drug: 14‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14‐mg nicotine patch
Study: 10234601
Drug: Nonprescription ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nonprescription ibuprofen (800 to 1200 mg/day for 1 to 10 days)
Study: 10234601
Drug: Nonprescription ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nonprescription ibuprofen
Study: 7795325
Drug: Counseling format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling format A (informed antibiotics are safe)
Study: 7795325
Drug: Counseling format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling format B (informed antibiotics are safe and about theoretical risk of diarrhea)
Study: 1674104
Drug: Beta-adrenergic-antagonist treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic-antagonist treatment (propranolol in 203 patients and nadolol in 83 patients)
Study: 6795245
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean dose, 3.1 mg/day)
Study: 6795245
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (mean dose, 1150 mg/day)
Study: 28661822
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment for substance abuse disorder
Study: 25374101
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU insulin detemir
Study: 21340475
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (mean dose 2.69 mg, mean duration 3.1 years)
Study: 10907116
Drug: Fasting split
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting split proinsulin and 30-min insulin concentrations
Study: 10907116
Drug: Fasting, split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting, split proinsulin and 30-min insulin concentrations
Study: 10907116
Drug: Insulin concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin concentrations
Study: 25981810
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sonidegib
Study: 25981810
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg sonidegib
Study: 24173657
Drug: Venlafaxine hydrochloride
Normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine hydrochloride extended release (up to 300 mg)
Study: 24173657
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride (up to 80 mg)
Study: 17180156
Drug: Intra‐dialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐dialytic parenteral nutrition (IDPN) with exercise
Study: 17180156
Drug: Intra‐dialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐dialytic parenteral nutrition (IDPN) alone
Study: 11997706
Drug: Dopamine D2-class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2-class receptor antagonist sulpiride
Study: 29519133
Drug: Fentanyl-soaked biodegradable
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-soaked biodegradable synthetic polyurethane foams packing (50 mcg)